CSIMarket
 
Celldex Therapeutics inc   (CLDX)
Other Ticker:  
 
 
Price: $40.9600 $-1.05 -2.499%
Day's High: $42.4 Week Perf: -11.05 %
Day's Low: $ 40.89 30 Day Perf: 11.3 %
Volume (M): 1,181 52 Wk High: $ 53.18
Volume (M$): $ 48,357 52 Wk Avg: $33.69
Open: $42.07 52 Wk Low: $22.11



 Market Capitalization (Millions $) 1,984
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -141
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 2

Celldex Therapeutics Inc
Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative immunotherapies to treat various types of cancer and other difficult-to-treat diseases. The company's goal is to harness the power of the immune system to combat diseases by targeting specific proteins and pathways that play a role in disease progression.

Celldex Therapeutics has a diverse pipeline of product candidates, which includes novel monoclonal antibodies, antibody-drug conjugates, and vaccines. These candidates are designed to target and stimulate the immune system to recognize and destroy cancer cells, while also reducing the toxic side effects associated with traditional chemotherapy treatments.

One of the company's lead candidates is Glembatumumab Vedotin, an antibody-drug conjugate currently in clinical trials for the treatment of triple-negative breast cancer. Another promising candidate is CDX-1140, a fully human monoclonal antibody that activates the immune system's natural killer cells to fight against cancer.

Celldex Therapeutics has established collaborations with other pharmaceutical companies and research institutions to further advance their product candidates. They are committed to advancing scientific knowledge and improving patient outcomes through research and development of innovative immunotherapies.


   Company Address: Perryville III Building Hampton 8827 NJ
   Company Phone Number: 200-7500   Stock Exchange / Ticker: NASDAQ CLDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

Celldex Therapeutics Raises Impressive $400 Million in Upsized Public Offering

Published Fri, Mar 1 2024 2:15 AM UTC

Celldex Therapeutics Announces Pricing of Upsized Public Offering, Expected to Raise $400.4 Million
Celldex Therapeutics, Inc. (Celldex), a biopharmaceutical company focused on developing targeted immunotherapies for the treatment of cancer and other diseases, made a significant announcement today regarding the pricing of an upsized underwritten public offering of its co...

Shares

Celldex Therapeutics Proposes a $250 Million Public Offering, Signaling Confidence in Future Growth and Advancement of Innovative Product Candidates

Published Wed, Feb 28 2024 9:01 PM UTC


Hampton, N.J., Feb. 28, 2024 - Celldex Therapeutics, Inc. (Nasdaq: CLDX) has recently announced its proposal to offer and sell shares of common stock in an underwritten public offering, with an added option for underwriters to purchase additional shares. This move comes in line with the company's commitment to continue clinical and preclinical development of its product...

Celldex Therapeutics Inc

Celldex Therapeutics Inc. Surges Past Competitors with 156% Revenue Growth in 2023

Celldex Therapeutics Inc. has proven its strong revenue growth, demonstrating a remarkable 156.107% increase year on year to reach $4.13 million in the most recent fiscal period. Despite an increased deficit per share at $-0.82, the surge in revenue during the fourth quarter of 2023 has positioned Celldex Therapeutics advantageously within the In Vitro & In Vivo Diagnostic Substances sector. Comparatively, its contemporaries in the same sector only experienced average top-line growth of 14.97% during the same period.
In the preceding reporting period, Celldex Therapeutics Inc. witnessed a significant improvement in its financials as its deficit per share increased from $-0.81 to $-0.82, while revenue doubled by an impressive 172.314% from $1.52 million. These numbers showcase the company's strong growth trajectory and financial stability.

Clinical Study

Celldex Therapeutics Reports Promising 12-Week Results for Barzolvolimab in Chronic Spontaneous Urticaria

Published Sat, Feb 24 2024 7:05 PM UTC

Celldex Therapeutics Presents Positive 12-Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaCelldex Therapeutics, a leading biopharmaceutical company, announced today the promising findings from their Phase 2 study evaluating the efficacy and safety of Barzolvolimab in patients with Chronic Spontaneous Urticaria (CSU). The study demonstrated signi...

Shares

Celldex Therapeutics Announces Public Offering to Advance Product Development Efforts

Published Tue, Nov 7 2023 9:02 PM UTC

Celldex Therapeutics Announces Proposed Public Offering of Common Stock for Continued Product Development
HAMPTON, N.J., Nov 07, 2023 - Celldex Therapeutics, Inc. (Nasdaq: CLDX), a leading biopharmaceutical company, has recently announced its plans to offer and sell shares of its common stock in an underwritten public offering, subject to market conditions. The company i...






 

Celldex Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Celldex Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Celldex Therapeutics inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com